Relmada (RLMD) Q2 2026 Earnings Call Transcript

Relmada Therapeutics reported Q2 2026 net loss of $12.9M ($0.11/share), narrower than last year’s $9.9M ($0.30/share), while cash increased to $217.7M (from $93M at 12/31/2025), extending its projected capital runway through 2029. The company reiterated IND filings by year-end 2026 for both NDV-01 (and sepranolone) and expects Phase 3 RESCUE enrollment to begin after IND clearance, with ~80 clinical sites planned (60 primary, 20 backup). Operational execution remains the key focus—especially NDV-01 GMP manufacturing scheduling and IND-enabling stability work—while Phase 2 efficacy showed 95% complete response at any time and 76% durable complete response at 12 months.

Analysis

This is no longer a pure clinical readout; it is a manufacturing-and-timing trade. The stock should trade more on whether management can de-risk CMC/IND execution than on the already-promoted efficacy signal, because small-cap biotech re-rates tend to hinge on proof of reproducibility, not slide-deck potency. The enlarged share count also matters: even with a long runway, dilution has already reset per-share expectations, so any additional delay would likely compress the multiple faster than the balance sheet can support it.

The important second-order implication is competitive, not just company-specific. If NDV-01 is truly simple to administer in community urology, it attacks the cost/complexity premium of bladder-preservation alternatives and could shift adoption away from higher-touch or more expensive intravesical approaches. That makes the first marketable read-through more relevant than the first efficacy data; if they show GMP batches and stability, the market will start discounting a broader office-based NMIBC franchise rather than a single asset.

Contrarian view: the consensus may be underweighting durability and overfocusing on headline response. In this setting, a therapy that is "good enough" but operationally easy can win share if repeat procedures and anesthesia avoidance matter to physicians and site economics. What would falsify the thesis is any further slip in the IND timeline, weak stability/CMC disclosure, or first-patient dosing moving materially past 1Q27; at that point this becomes a financing story again, and the runway narrative stops mattering.

Key Decisions for Investors

• Hold RLMD only as a small event-driven long into the year-end IND window; size it as a binary execution trade, not a core biotech position, because the downside is a timeline miss rather than a cash-burn crisis.
• If IND is filed on time, add on confirmation rather than anticipation; the cleaner entry is the 30-day post-filing FDA clock, when the market can start pricing first-patient dosing in 1Q27.
• Use a beta hedge if expressing the trade: long RLMD / short XBI for the next 1-3 months, since the catalyst is company-specific and broader biotech sentiment will otherwise swamp the signal.
• If management slips IND beyond year-end or does not show GMP/stability progress next update, exit immediately; that would likely reintroduce financing overhang and reverse the current de-risking setup.
• Watch CGON and the NMIBC basket for read-through: a clean CMC execution at RLMD would be a positive sentiment catalyst for office-based bladder-preservation names over the next 1-3 months.